InterMune (NASDAQ:ITMN)‘s stock had its “overweight” rating restated by stock analysts at JPMorgan Chase & Co. in a report issued on Tuesday. They currently have a $51.00 price objective on the stock, up from their previous price objective of $45.00. InterMune Inc (NASDAQ:ITMN) weekly performance is 8.07%. On last trading day company shares ended up $44.46. Analysts mean target price for the company is $40.79. InterMune Inc (NASDAQ:ITMN) distance from 50-day simple moving average is 27.43%.
Pernix Therapeutics Holdings (NYSE:PTX) was upgraded by analysts at Aegis to a “buy” rating in a research report issued to clients and investors on Tuesday. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) shares advanced 4.16% in last trading session and ended the day on $7.26. PTX Gross Margin is 50.20% and its return on assets is -11.20%. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) quarterly performance is 108.02%.
Analysts at Bank of America initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set a “buy” rating on the stock. Vital Therapies Inc (NASDAQ:VTL) shares moved up 0.09% in last trading session and was closed at $32.11, while trading in range of $30.12-$35.20. Vital Therapies Inc (NASDAQ:VTL) year to date performance is 167.83%.
Enzo Biochem (NYSE: ENZ) has been assigned U.S. Patent Office Patent No. 8,742,090, related to the construct of an artificial vector capable of greater efficiency, in general, in targeting specific cells in the application of gene therapy and gene transfer technology. Enzo Biochem, Inc. (NYSE:ENZ) ended the last trading day at $5.02. Company weekly volatility is calculated as 5.79% and price to cash ratio as 28.89. Enzo Biochem, Inc. (NYSE:ENZ) showed a positive weekly performance of 8.66%.
Bernstein began coverage on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Wednesday. The firm issued an outperform rating and a $30.00 price objective on the stock. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) weekly performance is 29.39%. On last trading day company shares ended up $20.34. Analysts mean target price for the company is $23.00. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) distance from 50-day simple moving average is 70.02%.